SCHEMBL4117014

SCHEMBL4117014

COc1ccc(CNc2ccc(C(F)(F)F)cc2C(O)c2cccc(OC)c2Cl)c(OC)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.43
TAS1R3 Q7RTX0 1/20 0.41
TAS1R1 Q7RTX1 1/20 0.41
MAPT P10636 3/20 0.41
GAA P10253 1/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
CYP1A2 P05177 8/20 0.39
CYP3A4 P08684 8/20 0.39
CYP2C19 P33261 8/20 0.39
TSHR P16473 7/20 0.39
CYP2D6 P10635 7/20 0.39
HSD17B10 Q99714 2/20 0.39
LMNA P02545 2/20 0.39
CLK4 Q9HAZ1 2/20 0.39
ALDH1A1 P00352 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MAPK1 P28482 1/20 0.39
CYP2C9 P11712 1/20 0.39
HIF1A Q16665 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4116912 0.90 TAS1R3 (0.42) RXFP1TAS1R3TAS1R1MAPTGAA
SCHEMBL13775822 0.90 TAS1R3 (0.42) RXFP1TAS1R3TAS1R1MAPTGAA
SCHEMBL4118899 0.90 TAS1R3 (0.42) RXFP1TAS1R3TAS1R1MAPTGAA
SCHEMBL4127861 0.89 TAS1R3 (0.44) TAS1R3TAS1R1MAPTGAAMEN1
SCHEMBL4122265 0.88 TAS1R3 (0.44) TAS1R3TAS1R1MAPTGAAMEN1
SCHEMBL4122733 0.87 TAS1R3 (0.44) TAS1R3TAS1R1MAPTGAAMEN1
SCHEMBL4111526 0.86 TAS1R3 (0.43) TAS1R3TAS1R1MAPTGAAMEN1
SCHEMBL4118845 0.85 TAS1R3 (0.40) TAS1R3TAS1R1MAPTGAAMEN1
SCHEMBL4123282 0.85 RXFP1 (0.39) RXFP1TAS1R3TAS1R1MAPTGAA
SCHEMBL4115101 0.83 TAS1R3 (0.41) TAS1R3TAS1R1MAPTGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
EP-1939205-A1 TRICYCLIC COMPOUND Daiichi Sankyo Company, Limited (JP) 2008-07-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181942-A1 TRICYCLIC COMPOUNDS FDFT1, COASY, HMGCR RXFP1 679/4885TAS1R3 3354/4885TAS1R1 2624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.